NLRP3 and cancer: Pathogenesis and therapeutic opportunities.
Caspase-1
IL-1 family
NLRP3
Pyroptosis
Response to therapy
Tumor microenvironment
Journal
Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
23
06
2023
revised:
20
09
2023
accepted:
02
10
2023
pmc-release:
01
11
2024
medline:
7
11
2023
pubmed:
23
10
2023
entrez:
22
10
2023
Statut:
ppublish
Résumé
More than a decade ago IL-1 blockade was suggested as an add-on therapy for the treatment of cancer. This proposal was based on the overall safety record of anti-IL-1 biologics and the anti-tumor properties of IL-1 blockade in animal models of cancer. Today, a new frontier in IL-1 activity regulation has developed with several orally active NLRP3 inhibitors currently in clinical trials, including cancer. Despite an increasing body of evidence suggesting a role of NLRP3 and IL-1-mediated inflammation driving cancer initiation, immunosuppression, growth, and metastasis, NLRP3 activation in cancer remains controversial. In this review, we discuss the recent advances in the understanding of NLRP3 activation in cancer. Further, we discuss the current opportunities for NLRP3 inhibition in cancer intervention with novel small molecules.
Identifiants
pubmed: 37866732
pii: S0163-7258(23)00209-7
doi: 10.1016/j.pharmthera.2023.108545
pmc: PMC10710902
mid: NIHMS1942634
pii:
doi:
Substances chimiques
Inflammasomes
0
Interleukin-1
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Reactive Oxygen Species
0
NLRP3 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
108545Subventions
Organisme : NIAID NIH HHS
ID : R01 AI015614
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest I.W.T. serves as consultant for Olatec and receives compensation. C.A.D. serves as Chairman of Olatec’s Scientific Advisory Board, is co-Chief Scientific Officer, receives compensation, and has equity in Olatec. C.M. serves as Director for Olatec’s Innovative Science Program and has equity in Olatec.
Références
J Clin Invest. 2020 May 1;130(5):2570-2586
pubmed: 32017708
Front Oncol. 2020 Aug 21;10:1378
pubmed: 32974137
Lancet Oncol. 2017 Feb;18(2):192-201
pubmed: 28094194
Biochem Biophys Res Commun. 2016 Aug 26;477(3):329-35
pubmed: 27343554
Cancer Immunol Res. 2023 Apr 3;11(4):400
pubmed: 36897261
Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):E961-E969
pubmed: 28096356
J Natl Cancer Inst. 1996 Feb 21;88(3-4):198-205
pubmed: 8632494
Oncogene. 2017 Jan 19;36(3):293-303
pubmed: 27321181
Front Immunol. 2013 Mar 08;4:50
pubmed: 23483669
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9
pubmed: 10639148
Cancer Res. 2018 Sep 15;78(18):5200-5202
pubmed: 30217872
Nat Immunol. 2008 Aug;9(8):847-56
pubmed: 18604214
Front Immunol. 2021 Jun 15;12:661939
pubmed: 34211462
Int J Biol Markers. 2022 Sep;37(3):314-321
pubmed: 35686324
Lab Invest. 2015 Jul;95(7):804-16
pubmed: 26006022
Nat Immunol. 2022 Apr;23(4):532-542
pubmed: 35332327
J Biol Chem. 2010 Feb 26;285(9):6477-88
pubmed: 20038581
Nature. 2014 May 15;509(7500):310-7
pubmed: 24828189
Science. 2016 Jun 3;352(6290):1232-6
pubmed: 27103670
Int J Mol Sci. 2021 Oct 15;22(20):
pubmed: 34681768
J Immunol. 2000 Mar 15;164(6):3330-6
pubmed: 10706727
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Radiat Oncol J. 2014 Sep;32(3):103-15
pubmed: 25324981
Immunol Rev. 2018 Jan;281(1):138-153
pubmed: 29247988
Gut. 2010 Sep;59(9):1192-9
pubmed: 20442201
BMC Cancer. 2018 May 2;18(1):500
pubmed: 29716544
J Biol Chem. 2016 Jan 15;291(3):1123-36
pubmed: 26555265
Cell Death Dis. 2018 Sep 20;9(10):946
pubmed: 30237538
Anticancer Res. 1996 Jan-Feb;16(1):437-41
pubmed: 8615650
Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):
pubmed: 33361152
Diagn Cytopathol. 2017 May;45(5):472-473
pubmed: 26870896
Oncol Lett. 2015 Mar;9(3):1015-1026
pubmed: 25663851
Nature. 2020 Jul;583(7817):609-614
pubmed: 32581358
Cancer Biol Ther. 2011 Jun 15;11(12):1008-16
pubmed: 21464611
Am J Hematol. 2016 Jun;91(6):571-4
pubmed: 26945843
Cancer Immunol Res. 2023 Feb 3;11(2):184-198
pubmed: 36478221
Cell Rep. 2020 Nov 17;33(7):108381
pubmed: 33207188
Immunity. 1999 Jan;10(1):127-36
pubmed: 10023777
Curr Opin Genet Dev. 2021 Feb;66:63-69
pubmed: 33422951
Cell Rep. 2014 Jul 24;8(2):570-82
pubmed: 25043180
Cancer Cell. 2018 Apr 9;33(4):634-648.e5
pubmed: 29551594
J Toxicol. 2011;2011:431287
pubmed: 22174709
Mol Cell Biochem. 2020 Jan;463(1-2):189-201
pubmed: 31612353
Sci Rep. 2016 May 25;6:26280
pubmed: 27221966
Br J Cancer. 2022 Sep;127(5):785-787
pubmed: 35739301
Nat Immunol. 2020 Jan;21(1):42-53
pubmed: 31768073
Cancer Immunol Res. 2023 Apr 3;11(4):421-434
pubmed: 36758176
J Immunol. 2017 Mar 1;198(5):2156-2164
pubmed: 28130493
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754
pubmed: 29654146
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1722-1730
pubmed: 31919284
J Immunol. 2006 Apr 1;176(7):3877-83
pubmed: 16547218
J Cardiovasc Pharmacol. 2019 Oct;74(4):285-296
pubmed: 31335445
PLoS One. 2012;7(4):e34977
pubmed: 22529966
Nat Genet. 2020 Nov;52(11):1219-1226
pubmed: 33106634
Cancer Metab. 2021 May 12;9(1):23
pubmed: 33980323
Oncotarget. 2016 May 10;7(19):28183-94
pubmed: 27058421
Cancer Res Commun. 2023 Sep 20;3(9):1899-1911
pubmed: 37772994
Blood. 2001 Aug 15;98(4):972-8
pubmed: 11493441
Biosci Rep. 2020 Jul 31;40(7):
pubmed: 32578856
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
Cells. 2023 Jan 31;12(3):
pubmed: 36766797
J Clin Lab Anal. 2021 Nov;35(11):e23973
pubmed: 34636069
J Cardiovasc Pharmacol. 2015 Jul;66(1):1-8
pubmed: 25915511
Blood. 1994 Dec 15;84(12):4242-8
pubmed: 7994038
Trends Immunol. 2021 Jul;42(7):575-589
pubmed: 34034975
Cancer Immunol Res. 2023 Jul 5;11(7):978-999
pubmed: 37099651
PLoS One. 2014 Feb 26;9(2):e89961
pubmed: 24587153
J Virol. 2005 Nov;79(22):13993-4003
pubmed: 16254335
Cell Death Dis. 2017 Feb 2;8(2):e2579
pubmed: 28151471
J Exp Clin Cancer Res. 2020 Aug 10;39(1):153
pubmed: 32778144
Sci Rep. 2016 Oct 27;6:36107
pubmed: 27786298
Int Immunopharmacol. 2022 Mar;104:108512
pubmed: 35026655
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7119-24
pubmed: 19359475
Cell Death Dis. 2021 Oct 30;12(11):1033
pubmed: 34718325
J Cell Biochem. 2018 Dec;119(12):9997-10004
pubmed: 30145830
Emerg Infect Dis. 2010 Nov;16(11):1671-7
pubmed: 21029523
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21635-40
pubmed: 21118981
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893937
Cancer Res Treat. 2020 Jan;52(1):181-188
pubmed: 31291714
Nat Immunol. 2009 Mar;10(3):241-7
pubmed: 19221555
Cancer Immunol Immunother. 2023 Sep;72(9):3003-3012
pubmed: 37289257
Front Immunol. 2013 Nov 20;4:391
pubmed: 24312098
Signal Transduct Target Ther. 2022 Sep 17;7(1):329
pubmed: 36115852
Cancer Lett. 2021 Jan 28;497:178-189
pubmed: 33091534
J Exp Med. 2006 Jul 10;203(7):1685-91
pubmed: 16818675
Curr Top Microbiol Immunol. 2015;390(Pt 1):267-85
pubmed: 26424650
Cell Res. 2011 Apr;21(4):558-60
pubmed: 21283134
Rheumatology (Oxford). 2011 Jul;50(7):1341-2
pubmed: 21489973
Immunity. 2018 Jan 16;48(1):35-44.e6
pubmed: 29195811
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207085
Cancer. 2009 Feb 15;115(4):859-68
pubmed: 19140204
Nat Med. 2013 Jan;19(1):57-64
pubmed: 23202296
Carcinogenesis. 2012 Nov;33(11):2126-34
pubmed: 22843550
Front Immunol. 2021 Aug 31;12:661323
pubmed: 34531850
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33649199
Cell Rep. 2020 Dec 22;33(12):108542
pubmed: 33357423
FEBS Lett. 2016 Feb;590(3):358-68
pubmed: 26831735
Biomed Pharmacother. 2019 Oct;118:109217
pubmed: 31302424
Science. 2017 Feb 24;355(6327):842-847
pubmed: 28104796
Clin Immunol. 2020 Apr;213:108373
pubmed: 32135277
Pharmaceuticals (Basel). 2020 Dec 30;14(1):
pubmed: 33396632
Clin Cancer Res. 2016 Mar 15;22(6):1432-44
pubmed: 26500238
Nat Immunol. 2021 May;22(5):550-559
pubmed: 33707781
J Exp Med. 2010 May 10;207(5):1045-56
pubmed: 20385749
Nature. 2023 Apr;616(7955):159-167
pubmed: 37020004
Onco Targets Ther. 2020 Dec 14;13:12787-12796
pubmed: 33363384
Cytokine. 2001 Jun 21;14(6):334-42
pubmed: 11497494
Arch Toxicol. 2022 Apr;96(4):1075-1087
pubmed: 35190838
Int J Mol Sci. 2021 Jun 24;22(13):
pubmed: 34202728
Cancer Res. 2010 Dec 15;70(24):10161-9
pubmed: 21159638
Nat Commun. 2021 Jan 28;12(1):653
pubmed: 33510147
Mol Cancer Ther. 2021 Nov;20(11):2280-2290
pubmed: 34518296
Immunity. 2015 Oct 20;43(4):751-63
pubmed: 26384545
Cell Res. 2015 Dec;25(12):1285-98
pubmed: 26611636
Mucosal Immunol. 2014 May;7(3):684-93
pubmed: 24172847
J Exp Med. 2017 Jun 5;214(6):1711-1724
pubmed: 28442553
PLoS One. 2014 Jun 05;9(6):e98899
pubmed: 24901306
Transplant Direct. 2015 Dec 15;2(1):e48
pubmed: 27500242
Drug Des Devel Ther. 2016 Nov 15;10:3755-3761
pubmed: 27895465
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Nat Commun. 2013;4:2909
pubmed: 24352507
J Immunol. 1987 Jul 15;139(2):464-8
pubmed: 3298430
Cell Mol Life Sci. 2018 Jun;75(11):2045-2058
pubmed: 29184980
JCI Insight. 2022 Aug 8;7(15):
pubmed: 35788117
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
pubmed: 16916931
JAMA Cardiol. 2019 Apr 1;4(4):380-387
pubmed: 30865214
Nephrol Dial Transplant. 2018 May 1;33(5):881-889
pubmed: 29342279
Cancer Res. 1994 May 15;54(10):2667-72
pubmed: 8168095
Cancer Res. 2018 Sep 15;78(18):5243-5258
pubmed: 30012670
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Oncotarget. 2016 Nov 15;7(46):75571-75584
pubmed: 27765923
Pharmaceuticals (Basel). 2022 May 04;15(5):
pubmed: 35631400
Clin Cancer Res. 2019 Jul 1;25(13):3772-3775
pubmed: 30890552
Cancer Res. 1997 Jul 1;57(13):2602-5
pubmed: 9205063
N Engl J Med. 2017 Jul 13;377(2):111-121
pubmed: 28636844
Lab Invest. 2014 Jan;94(1):52-62
pubmed: 24166187
Environ Toxicol Pharmacol. 2015 Mar;39(2):917-26
pubmed: 25805627
Pigment Cell Melanoma Res. 2012 Jul;25(4):506-13
pubmed: 22524199
Cancer Res. 2021 Jan 1;81(1):144-157
pubmed: 33122306
Carcinogenesis. 2015 Jun;36 Suppl 1:S128-59
pubmed: 26106135
J Cancer Res Clin Oncol. 2010 May;136(5):709-16
pubmed: 19904560
J Exp Med. 2005 Dec 19;202(12):1691-701
pubmed: 16365148
Cancer Lett. 2014 Apr 10;345(2):196-202
pubmed: 23981572
Oncotarget. 2017 Jul 25;8(30):48972-48982
pubmed: 28430665
Annu Rev Biochem. 2005;74:355-83
pubmed: 15952891
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32244867
Cold Spring Harb Symp Quant Biol. 2013;78:117-24
pubmed: 24092469
Nature. 2022 Dec;612(7939):301-309
pubmed: 36450978
Hematol Oncol Clin North Am. 1999 Dec;13(6):1117-25
pubmed: 10626139
Nat Rev Immunol. 2023 Sep;23(9):595-610
pubmed: 36941354
Oncol Lett. 2017 Dec;14(6):7031-7044
pubmed: 29344132
Mol Med Rep. 2019 Oct;20(4):3424-3432
pubmed: 31432144
Sci Rep. 2020 Apr 20;10(1):6640
pubmed: 32313131
Transl Res. 2023 Feb;252:9-20
pubmed: 35948198
Nat Rev Immunol. 2013 Jun;13(6):397-411
pubmed: 23702978
Immunol Cell Biol. 2012 Nov;90(10):983-6
pubmed: 23010873
Sci Signal. 2023 Jan 17;16(768):eabh1083
pubmed: 36649377
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Transl Lung Cancer Res. 2022 May;11(5):858-868
pubmed: 35693281
J Control Release. 2007 Nov 6;123(2):123-30
pubmed: 17900737
Oncogene. 2019 Jan;38(2):194-208
pubmed: 30087439
J Clin Invest. 2022 Jun 1;132(11):
pubmed: 35642641
Ann Am Thorac Soc. 2014 Mar;11(3):303-9
pubmed: 24423399
Nat Commun. 2016 Mar 14;7:10791
pubmed: 26972847
Cell Rep. 2017 Sep 26;20(13):3025-3033
pubmed: 28954221
Lancet Oncol. 2014 Aug;15(9):966-74
pubmed: 25042199
Biomaterials. 2023 May;296:122062
pubmed: 36863071
Sci Signal. 2021 Apr 27;14(680):
pubmed: 33906973
Semin Cutan Med Surg. 2011 Dec;30(4):222-8
pubmed: 22123420
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Oncotarget. 2017 Sep 18;8(65):108571-108583
pubmed: 29312552
Proc Natl Acad Sci U S A. 2015 Sep 8;112(36):11318-23
pubmed: 26305961
J Exp Clin Cancer Res. 2017 Jun 21;36(1):81
pubmed: 28637493
Int J Environ Res Public Health. 2022 Feb 27;19(5):
pubmed: 35270479
Immunity. 2017 Oct 17;47(4):697-709.e3
pubmed: 29045901
J Clin Oncol. 2023 Mar 1;41(7):1423-1433
pubmed: 36480766
Nature. 2011 Jan 13;469(7329):221-5
pubmed: 21124315
Nat Commun. 2020 Apr 3;11(1):1659
pubmed: 32246016
Nat Commun. 2019 Sep 26;10(1):4375
pubmed: 31558756
Immunity. 2019 Jun 18;50(6):1412-1424.e6
pubmed: 31076360
Immunity. 2016 Apr 19;44(4):833-46
pubmed: 27037191
Oncol Res. 2019 Jul 12;27(7):827-834
pubmed: 30940293
Vaccine. 2009 May 26;27(25-26):3331-4
pubmed: 19200813
Inflamm Res. 2022 Jan;71(1):141-155
pubmed: 34854954
Arch Immunol Ther Exp (Warsz). 2015 Dec;63(6):485-94
pubmed: 26253076
J Exp Med. 2013 Mar 11;210(3):491-502
pubmed: 23460726
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
Cancer Metastasis Rev. 2010 Jun;29(2):317-29
pubmed: 20422276
Immunol Rev. 2017 Mar;276(1):121-144
pubmed: 28258700
Arch Toxicol. 2023 Apr;97(4):1047-1068
pubmed: 36847822